United Therapeutics Remodulin Efficacy Shown By Secondary Data - Cmte.
Executive Summary
United Therapeutics' Remodulin efficacy may be based on secondary measures rather than primary endpoints because the pulmonary arterial hypertension therapy will be prescribed for a small population, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed at its Aug. 9 meeting.
You may also be interested in...
United Therapeutics Filling $9 Mil. Of Remodulin Orders Following Approval
United Therapeutics is filling $9 mil. worth of distributors' advance purchase orders for Remodulin following accelerated approval of the drug for treatment of pulmonary hypertension May 21
United Therapeutics Filling $9 Mil. Of Remodulin Orders Following Approval
United Therapeutics is filling $9 mil. worth of distributors' advance purchase orders for Remodulin following accelerated approval of the drug for treatment of pulmonary hypertension May 21
United Therapeutics Remodulin “approvable”
United Therapeutics will conduct a two-year postmarketing study for its pulmonary arterial hypertension therapy Remodulin (treprostinil) after an FDA "approvable" letter. The Cardio-Renal Advisory Committee found that secondary measures in the pivotal trial suggested efficacy which could support accelerated approval (1"The Pink Sheet" Aug. 13, 2001, p. 21). The company expects approval in several months, following labeling discussions...